Mission Hospital Inc-Memorial Campus | ClinicalTrials HQ

5 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma	Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell myeloma, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Active, not recruiting	Phase 3	2026-10-05		NCT01863550
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers	Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma AJCC v7	Active, not recruiting	Phase 3	2026-06-09		NCT02785952
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer	Neoplasms by Site, Skin and Connective Tissue Diseases, breast adenocarcinoma, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma	Active, not recruiting	Phase 3	2026-05-06		NCT02488967
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies	Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, hematologic disorder, leukemia, neoplasm	Active, not recruiting	Not stated	2026-04-06		NCT00736749
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer	Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, male breast carcinoma, neoplasm, skin disorder	Active, not recruiting	Phase 3	2026-02-10		NCT01674140